Loading…
BillionToOne, Inc.
🏹 Trader: 🎯 Near 52W High 💎 VCP Breakout View all →
$2.1B
Market Cap
584.6
P/E
PEG
16.9%
ROCE
7.1%
ROE
0.22
D/E
5.3%
OPM
+0.0%
% from 52W High
93
α RS
⚖️ Compare 🔒 Generate Report 📚 Guides
🌏 Global Investor Returns
Currency-adjusted total returns for BLLN including FX impact
🌏
Click 🌏 Returns tab to load data
📈 Price History
Ratio Health
Excellent
Good
Average
Poor
By Category
📊 Sector Averages
Key Ratios Snapshot
📈 Growth Pattern
📊 Quick Scorecard
Loading…
⭐ Superinvestors Holding BLLN
View All Superinvestors →
Manager Shares Value % of Fund Period
Jim Simons Renaissance Technologies LLC 51.3K $4.0M 0.01% Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔒
Premium Feature
AI-generated 10-section company profile — business model, financials, strengths, risks & management quality
Upgrade to Premium
Already a member? Log in
📐
3-Statement Financial Model
Bear / Base / Bull projections · DCF fair value · Reverse-DCF
Open Model →
🎙 Management Tone Mixed → Stable 3 quarters Full tone analysis in Intelligence →
📊 MIXED Q1 2026 revenue $108.4M, 84% YoY growth, GAAP operating margin 16%, 44% test volume growth
Revenue & Profitability
Total revenue in Q1 2026 was $108.4 million, up 84% year-over-year. Net income available to common shareholders was $18.0 million ($0.34 per diluted share), compared to a net loss of $4.0 million in Q1 2025. Operating income was $17.8 million, representing a 16% GAAP operating margin. Adjusted EBITDA margin was 24%. Cash and equivalents stood at $537.5 million at quarter end.
Outlook
Management sees a large and growing market, estimating the U.S. opportunity for prenatal and oncology cfDNA at over $100 billion over time. They expect continued strong demand driven by multiple reinforcing factors: product innovation, expanding payer coverage, and clinical evidence. Specific macro headwinds mentioned include seasonality (Q4 slower due to holidays) and the temporary reset of coinsurance/deductibles at the start of the year.
Growth Drivers
Growth is driven by 44% year-over-year test volume growth (prenatal +10% QoQ, oncology +25% QoQ) and 28% ASP expansion to $571 per test. New product launches (UNITY Confirm, Fetal Antigen NIPT, PGx, CH) and in-network contracts (Anthem, UnitedHealthcare) support ASPs. Oncology growth is particularly strong, with Northstar Select and Response adoption, and a 2:1 ratio of Response to Select tests. The company expects the oncology ramp to continue.
Balance Sheet & CapEx
Not discussed in this earnings call. The company mentioned efficient operations incorporating AI and automation, and achieved positive cash flow ($11 million after capex in Q1), but no specific capex guidance or investment amounts were provided.
Margins
Gross margin was 73% in Q1 2026, up 9 percentage points year-over-year, driven by higher prenatal ASPs and oncology COGS reductions. COGS per test was $153, down 5% sequentially. Management expects overall gross margins to remain above 70% for the year, with potential quarterly volatility due to faster oncology growth. Long-term, both segments target above 75% gross margins.
Key Risks
Risks flagged include seasonality (Q4 slower due to holidays), resetting of coinsurance/deductibles at year-start affecting ASPs temporarily, and the variable timeline for health system adoption. The faster growth of oncology (lower-margin) could pressure overall margins. There is a risk of delays in MolDX coverage decisions, but management stated they are on track and not seeing issues. No other macro risks were discussed.
Generated by AI · Q1 2026 results · Not investment advice
🔒
Free Account Required

Create a free Finmagine account to access Finmagine™ Scorecard.

See how this company scores across 5 dimensions — Financial Health, Growth Prospects, Competitive Position, Management Quality, and Valuation — powered by 30+ computed ratios.

Create Free AccountLog In
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Ask AI.

Get 25 expert AI analysis templates — Business KPIs, Comprehensive, Forensic Governance, Peer Comparison, Risk-Reward, Full Research Report, IPO Decoder, Red Flag Detector, and more — ready to paste into ChatGPT, Claude, Gemini, or Perplexity.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Peer Comparison.

Compare this company side-by-side against its sector peers with financial metrics, ratio benchmarking, and relative performance across all key dimensions.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Documents.

Access concall transcripts, annual reports, credit ratings, and investor presentations.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Full Report.

Read the complete Finmagine™ investment research report — comprehensive fundamental analysis, business model assessment, competitive positioning, and investment recommendation.

Upgrade to PremiumCreate Free Account

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯
Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.
📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

Financial Model
Projections are built from each company's audited annual financials (Income Statement, Balance Sheet, Cash Flow) over the last 5 fiscal years. Forward assumptions — revenue growth %, EBITDA margin, D&A (USD millions), interest expense, tax rate, and capex — are AI-generated using historical context and refreshed twice a year: after the December results season and after the September/Q4 results season.

DCF Valuation
Fair Value = Σ(FCFt / (1+WACC)t) + Terminal Value. Terminal Value uses the Gordon Growth Model: FCF5 × (1+g) / (WACC−g). Default WACC: 10% (US risk-free ~4.5%, equity risk premium ~5.5%). Default terminal growth: 3% (long-run US nominal GDP proxy).

CAGR Tracker
Expected 5-year CAGR = (DCF Fair Value / Current Price)1/5 − 1. Assumes fair value is reached in exactly 5 years — a mechanical estimate only.

Data Sources & Limitations
Financial statements sourced from public filings. Prices updated daily. Forward assumptions are AI-generated. All monetary values in USD millions. Non-US ADR companies may have currency conversion inaccuracies. Models are point-in-time and do not update intra-quarter or account for M&A, macro shocks, or extraordinary items.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.